Mixed Chimeric Transplantation for Primary Amyloidosis

N/AWithdrawnNCT00186095

Stanford University

Overview

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Amyloidosis

Interventions

autologous followed by nonmyeloablative allogeneic transplantPROCEDURE

Eligibility

Sex: ALLMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * primary amyloidosis * adequate organ function * matched sibling donor Exclusion Criteria: * evidence of multiple myeloma * HIV positive

Outcomes

Primary Outcomes

Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcomes

Toxicity of therapy

Changes in marrow and serum abnormalities

Improvement in end-organ function.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.